Alder to present Phase 3 Eptinezumab results at AAN 2018

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced that it will present new Phase 3 data for eptinezumab, Alder’s lead investigational product candidate for migraine prevention, at the 70th Annual American Academy of Neurology Meeting (AAN) in Los Angeles being held April 21-27, 2018.

Eptinezumab will be the subject of eight scientific presentations. These will include new data from Alder’s PROMISE 1 Phase 3 clinical trial in episodic migraine patients following the third and fourth quarterly infusions (i.e., 12-month data) and improvement in patients’ quality of life measures following a single quarterly infusion. Data from the Company’s PROMISE 2 Phase 3 clinical trial in chronic migraine patients has also been selected for one of AAN’s two plenary presentation sessions on Emerging Science clinical trials.

“We are excited to present data from our PROMISE 1 and PROMISE 2 clinical studies at AAN, which further support eptinezumab’s differentiated clinical profile and its rapid, effective and sustained migraine prevention benefits,” said Roger K. Cady, M.D., Alder’s Vice President of Neurology. “There is a high unmet need for new treatment options to treat the millions of patients that continue to struggle with the burden of migraine. Eptinezumab’s consistent and predictable results across both trials support its potential to be a meaningful treatment option for the most severely impacted of these patients and Alder’s goal to advance the treatment paradigm for migraine prevention.”

Eptinezumab is an investigational monoclonal antibody targeting calcitonin gene-related peptide (CGRP) for migraine prevention. Eptinezumab’s mAb design, combined with delivery via quarterly infusion, allows for strong and immediate inhibition of CGRP biology.¹ Eptinezumab has been studied in several global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention.

Oral Presentations:

Clinical Trials Plenary Presentation

Session: Emerging Science
Tuesday, April 24, 2018, 11:00 a.m. – 11:15 a.m. PT, Concourse Hall 152-153

• A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE 2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Trial.
  • Presenter: Dr. Richard Lipton, Director of the Montefiore Headache Center, Albert Einstein College of Medicine

Platform Presentations

Session S20: “Best of” Session: Headache Scientific
Tuesday, April 24, 2018, 8:00 a.m. – 8:08 a.m. PT, Convention Center – 515 B

• Primary Results of PROMISE 1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines.
  • Presenter: Dr. Stephen Silberstein, Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University

Session S32: Headache: Therapeutics Scientific
Wednesday, April 25, 2018, 1:12 p.m. – 1:24 p.m. PT, Convention Center – 402 AB

• Increased Migraine-Free Intervals With Eptinezumab Were Associated With Improved Health-Related Quality-of-Life Outcomes Through Week 12: Results From the Phase 3 PROMISE 1 Trial.
  • Presenter: Dr. Richard Lipton, Director of the Montefiore Headache Center, Albert Einstein College of Medicine

Poster Presentations:

Wednesday, April 25, 2018 – 11:30 a.m. – 7:00 p.m. PT, Convention Center – West Exhibit Hall

• P4 092: Eptinezumab Achieved Meaningful Reductions in Migraine Activity Within 24 Hours That Were Sustained Through Week 12: Results From PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Phase 3 Trial.
  • Presenter: Dr. Timothy Smith, Medical Director of Mercy Health Research, Mercy Medical Group
• P4 108: Repeat Infusions of Eptinezumab Associated With Greater Migraine Reductions and Longer Migraine-Free Intervals: Results From the Phase 3 PROMISE 1 Trial.
  • Presenter: Dr. Egilius Spierings, Director and Principal Investigator, MedVadis Research Corporation
• P4 091: Eptinezumab Reduced Migraine Frequency, Duration, and Pain Intensity Through Week 24: Results From the Phase 3 PROMISE 1 Trial.
  • Presenter: Dr. Peter McAllister, Director of the New England Center for Neurology and Headache
• P4 470 (Emerging Science): Eptinezumab Achieved Meaningful Reductions in Migraine Activity As Early As Day 1 and Were Sustained Through Week 12: Results From PROMISE 2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Phase 3 Trial in Chronic Migraine.
  • Presenter: Dr. David Kudrow, Director of the California Medical Clinic for Headache
• P4 471 (Emerging Science): Eptinezumab Reduced Migraine Frequency and Triptan/Ergotamine Use Over Weeks 1-12, and Improved HIT-6 Scores at Months One and Three: Results From the Phase 3 PROMISE 2 Trial in Chronic Migraine.
  • Presenter: Dr. Stephen Silberstein, Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/

News Source: AlderBio website

Image Source: https://www.medicalnewstoday.com/articles/319815.php